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1,2 Therefore, approaches using adoptive immunotherapies offer attractive alternative options for this subgroup of patients. While infused monoclonal antibodies have been proved to offer success as cancer immunotherapies, it is much more difficult to exploit the equivalent promise of T-cell immunotherapy. This dilemma is two-fold, comprising the significant time required to generate T cells for infusion and the relative lack of persistent in vivo expansion of the adoptively transferred cells, making it difficult to achieve sustained clinical responses. This article will focus on the T-cell therapies available in the treatment of multiple-relapsed or refractory lymphomas, and some of the strategies in place to overcome these obstacles.
Immunotherapeutic Options
Adoptive T-cell immunotherapy approaches to treating lymphomas have Table 1 ).
Unmanipulated Allogeneic T Cells (Donor Lymphocyte Infusion)
Perhaps the best known and most widely utilized form of immunotherapy for any malignancy is the use of unmanipulated allogeneic T cells, otherwise known as donor lymphocyte infusions (DLI), following allogeneic hematopoietic SCT. It is now understood that lymphomas can be sensitive to the effects of DLI with varying success rates. [3] [4] [5] [6] [7] In general, response rates are higher in patients with HD or low-grade lymphoma than in those with high-grade lymphoma. Unfortunately, DLI is limited by potentially fatal complications that arise from alloreactive T cells also present in the lymphocyte infusion, 8 as the benefit of any GvL effect is often directly associated with graft-versus-host disease (GvHD).
The first reports of successful DLI in lymphoma patients were in those who developed EBV-post-transplant lymphoproliferative disorder (EBV-LPD) following allogeneic SCT. 9 DLI was ideal in this setting because this malignancy is normally controlled by an EBV-specific T-cell response.
Since most EBV-seropositive individuals have a high frequency of EBVspecific precursors, the transfer of unmanipulated DLI should be able to restore the immune response to EBV. When DLI was used in this setting, the overall response rate was high, with 20 of 22 patients achieving complete remissions in one study. 10 However, other centers have seen lower response rates to DLI, possibly reflecting differing patient populations or suboptimal EBV-specific immune responses in donors.
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There have also been several groups who have used DLI for the treatment of residual HD or NHL following allogeneic SCT, with better successes reported in low-grade (over 60%) compared with high-grade lymphomas. 3, 6, 7, 12 The presence of any significant graft-versus-Hodgkin lymphoma activity following allogeneic SCT has proved difficult to establish, and may be hampered by the high treatment-related mortality rates in this heavily pre-treated patient population. However, transplant registry-based studies report that relapse rates are lower in HD patients who develop GvHD than in those who do not. 15 Further investigations of DLI approaches in lymphomas are clearly warranted; however, the development of strategies to maximize efficacy and minimize toxicity is crucial if this therapy is to play a major role in the treatment of lymphomas.
Autologously Expanded Non-specific T Cells
Enhanced recovery of lymphocyte counts has been correlated with improved outcome following autologous SCT for both HD and NHL. 16 To expand on this transient. 18 While it is not clear whether this approach will be efficacious in permitting durable clinical responses of relapsed disease, there may be some benefit in the setting of minimal residual disease.
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Recipients of Stem Cell Transplants
Consequently, our group and others have used EBV-specific CTL (EBV-CTL) generated using donor lymphocytes stimulated with EBV-transformed B cells
to expand an EBV-specific CTL population. 19, [23] [24] [25] [26] We have now used donor- transplanted for an EBV-related malignancy. 19, 25, 27 None of the patients developed EBV-LPD compared with 11.5% in a historical non-treated control group. 25 Gene marking confirmed the persistence of these CTL in vivo for as long as seven years post-infusion. 28 Similar results were seen by another group, who used EBV-CTL as prophylaxis in six T-cell depleted SCT recipients, with five of the six achieving a reduction in viral load. 26 Immunotherapy using EBV-CTL has also been used to treat overt lymphoma, with five of six patients treated successfully. 25 
Recipients of Solid-organ Transplants
Generating EBV-CTL for clinical use after SOT offers a unique dilemma in that the SOT donor is not human leukocyte antigen (HLA)-matched, and the EBV-associated LPD/lymphoma arises from recipient lymphocytes rather than being donor-derived. Therefore, the vast majority of studies have used autologously generated EBV-CTL. [29] [30] [31] While many of these studies indicate that autologous EBV-CTL can induce remissions of EBV-LPD, the persistence of these CTL appears to be less than that observed using donor-derived CTLs, implying that long-term immunosuppressive therapy in the SOT recipients may compromise CTL persistence and function. Since autologous CTL generation is a time-consuming process, two groups have used banked allogeneic partially HLA-matched EBV-CTL with some success. However, these results were confounded as some patients received additional antiviral therapies and some had dose reductions of their immunosuppressives, leaving the contribution of the allogeneic CTL in question.
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Epstein-Barr Virus-associated Lymphomas
Expressing Type 2 Latency Since our previous experience using EBV-CTL for relapsed EBV-HD generated CTL lines with low frequencies of cells specific for LMP2, we have now focused our efforts on using genetically modified tumor APCs that overexpress LMP2 as a strategy to increase the frequency of LMP2-specific EBV-CTL. To do this, we replaced the LCLs as APCs with dendritic cells (DCs) engineered to express LMP2 from an adenovirus (Ad)
vector for the primary stimulation, and then used the LCLs overexpressing LMP2 with the same Ad vector for subsequent stimulations (see Figure   1 ). 36 We have now used these genetically engineered LMP2-specific CTL in a dose-escalation study for 16 patients with high-risk EBV-HD and NHL.
Ten patients received CTL as adjuvant therapy with nine remaining in Step 2. complete remission for up to 37 months. 37 In addition, five of six patients with active, relapsed disease at the time of LMP2-specific CTL administration showed a tumor response, which was complete in four and sustained for more than nine months. No short-or long-term toxicities were observed after CTL infusion. 37 To expand on this concept, we are now extending these studies using autologous T cells enriched for both LMP1 and LMP2 for the treatment of EBV-positive lymphoma, with a clinical trial under way. 
Ad5F35LMP2-transduced LCL generation. An LCL line is generated from infecting PBMCs with a laboratory strain of EBV (B95-8). These LCLs are then transduced with the Ad5F35LMP2a vector and cultured for two days before being ready to be irradiated for use as the second and subsequent stimulators for LMP-specific CTL generation.
LMP2-specific CTLs
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Escaping Immune Evasion Mechanisms
Immune escape by tumor cells is made possible by a variety of mechanisms, such as the secretion of inhibitory cytokines by the malignant cells or downregulation of major histocompatibility complex and co-stimulatory molecules. For example, transforming growth factor-β (TGF-β), which is secreted by a wide variety of tumors, has detrimental effects on CTL proliferation and function. 47, 48 In fact, transgenic mice genetically engineered so that their T cells are insensitive to TGF signaling are able to eradicate tumors. 49 Our group has been interested in the role of dominant-negative TGF-β type 2 receptor (DNR)-transduced CTL in eradicating tumors given that others have shown that the adoptive transfer of such cells is able to eradicate tumor cells in murine models. 50 We have shown in human in
Perhaps the greatest limitation of cytotoxic T lymphocytes therapy is the time needed for ex vivo expansion.
Clinical studies had already shown expansion of T cells specifically for antigens expressed on solid tumors such as melanoma following lymphodepletion.
